Efficacy and safety results from a phase I/IIa study of dabrafenib in pediatric patients with BRAF V600-mutant relapsed refractory low-grade glioma.

被引：13
|
作者：
Kieran, Mark W.
Bouffet, Eric
Broniscer, Alberto
Cohen, Kenneth J.
Geoerger, Birgit
Hansford, Jordan R.
Hingorani, Pooja
Aerts, Isabelle
Andre, Nicolas
Bertozzi-Salamon, Anne-Isabelle
Dunkel, Ira J.
Hummel, Trent Ryan
Leary, Sarah
Moreno, Lucas
Russo, Mark W.
Tseng, Lillian
Dasgupta, Kohinoor
Nebot, Noelia
Whitlock, James
Hargrave, Darren R.
机构：
[1] Harvard Med Sch, Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA
[2] Univ Toronto, Hosp Sick Children, Toronto, ON, Canada
[3] St Jude Childrens Res Hosp, Memphis, TN USA
[4] Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Univ Paris Sud, Gustave Roussy Dept Childhood & Adolescent Oncol, Villejuif, France
[6] Univ Melbourne, Murdoch Childrens Res Inst, Royal Childrens Hosp, Melbourne, Australia
[7] Phoenix Childrens Hosp, Phoenix, AZ USA
[8] PSL Res Univ, Inst Curie, Oncol Ctr SIREDO, Paris, France
[9] Aix Marseille Univ, Childrens Hosp La Timone, AP HM, Marseille, France
[10] CHU Toulouse Pole Pediatr, Toulouse, France
[11] Mem Sloan Kettering Canc Ctr, New York, NY USA
[12] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH USA
[13] Seattle Childrens Hosp, Canc & Blood Disorders Ctr, Seattle, WA USA
[14] Hosp Univ Nino Jesus, Madrid, Spain
[15] Novartis Pharmaceut, E Hanover, NJ USA
[16] Novartis Healthcare Pvt Ltd, Hyderabad, India
[17] Great Ormond St Hosp Sick Children, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.10506
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10506
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma
    Saiag, P.
    Robert, C.
    Grob, J. J.
    Mortier, L.
    Dereure, O.
    Lebbe, C.
    Mansard, S.
    Grange, F.
    Neidhardt, E-M.
    Lesimple, T.
    Machet, L.
    Bedane, C.
    Jeudy, G.
    Aubin, F.
    Dreno, B.
    Szenik, A.
    Denden, A.
    Dutriaux, C.
    [J]. ANNALS OF ONCOLOGY, 2018, 29
  • [32] The anti-PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I
    Long, Georgina V.
    Lebbe, Celeste
    Atkinson, Victoria
    Mandala, Mario
    Nathan, Paul D.
    Arance, Ana
    Richtig, Erika
    Yamazaki, Naoya
    Robert, Caroline
    Schadendorf, Dirk
    Tawbi, Hussein Abdul-Hassan
    Ascierto, Paolo Antonio
    Ribas, Antoni
    Flaherty, Keith
    Lee, Dung-Yang
    Masood, Aisha
    Gasal, Eduard
    Dummer, Reinhard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [33] A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study
    Banerjee, Anuradha
    Jakacki, Regina I.
    Onar-Thomas, Arzu
    Wu, Shengjie
    Nicolaides, Theodore
    Poussaint, Tina Young
    Fangusaro, Jason
    Phillips, Joanna
    Perry, Arie
    Turner, David
    Prados, Michael
    Packer, Roger J.
    Qaddoumi, Ibrahim
    Gururangan, Sridharan
    Pollack, Ian F.
    Goldman, Stewart
    Doyle, Lawrence A.
    Stewart, Clinton F.
    Boyett, James M.
    Kun, Larry E.
    Fouladi, Maryam
    [J]. NEURO-ONCOLOGY, 2017, 19 (08) : 1135 - 1144
  • [34] Final results of a phase II study to evaluate the efficacy and safety of treatment and retreatment with rituximab in relapsed follicular or low-grade NHL.
    López, A
    Palacios, C
    Pérez-Manga, G
    Flores, E
    Funes, HC
    de la Serna, J
    Moreno, JA
    Bernabé, R
    Murias, A
    López, JJ
    Rueda, A
    Pérez, V
    [J]. BLOOD, 2001, 98 (11) : 604A - 604A
  • [35] Phase I Study of Fluvastatin-Celecoxib Combination in Children with Relapsing/Refractory Optico-Chiasmatic Low-Grade Glioma or High Grade Glioma (FLUVABREX): First Results
    Andre, N.
    Sterin, A.
    Solas, C.
    Le Deley, M. C.
    Bruneel, E. Tresch
    Probst, A.
    Aerts, I.
    Faure-Conter, C.
    Bertozzi, A. I.
    Chastagner, P.
    Entz-Werle, N.
    De Carli, E.
    Bouche, G.
    Leblond, P.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S427 - S428
  • [36] Overall Survival of Patients With Unresectable or Metastatic BRAF V600-Mutant Acral/Cutaneous Melanoma Administered Dabrafenib Plus Trametinib: Long-Term Follow-Up of a Multicenter, Single-Arm Phase IIa Trial
    Mao, Lili
    Ding, Ya
    Bai, Xue
    Sheng, Xinan
    Dai, Jie
    Chi, Zhihong
    Cui, Chuanliang
    Kong, Yan
    Fan, Yun
    Xu, Yanjun
    Wang, Xuan
    Tang, Bixia
    Lian, Bin
    Yan, Xieqiao
    Li, Siming
    Zhou, Li
    Wei, Xiaoting
    Li, Caili
    Guo, Jun
    Zhang, Xiaoshi
    Si, Lu
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis
    Gorodezki, David
    Zipfel, Julian
    Queudeville, Manon
    Sosa, Jordana
    Holzer, Ursula
    Kern, Jan
    Bevot, Andrea
    Schittenhelm, Jens
    Naegele, Thomas
    Ebinger, Martin
    Schuhmann, Martin U.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2022, 160 (03) : 567 - 576
  • [38] Resection extent and BRAF V600E mutation status determine postoperative tumor growth velocity in pediatric low-grade glioma: results from a single-center cohort analysis
    David Gorodezki
    Julian Zipfel
    Manon Queudeville
    Jordana Sosa
    Ursula Holzer
    Jan Kern
    Andrea Bevot
    Jens Schittenhelm
    Thomas Nägele
    Martin Ebinger
    Martin U. Schuhmann
    [J]. Journal of Neuro-Oncology, 2022, 160 : 567 - 576
  • [39] ePharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study
    Huw, Ling-Yuh
    Li, Feifei
    Belousov, Anton
    Ramesha, Hemanth
    Bolen, Christopher R.
    Wei, Michael C.
    Yin, Shen
    Turner, David C.
    Penuel, Elicia
    [J]. BLOOD, 2022, 140 : 6448 - 6449
  • [40] Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study
    Long, G. V.
    Flaherty, K. T.
    Stroyakovskiy, D.
    Gogas, H.
    Levchenko, E.
    de Braud, F.
    Larkin, J.
    Garbe, C.
    Jouary, T.
    Hauschild, A.
    Chiarion-Sileni, V.
    Lebbe, C.
    Mandala, M.
    Millward, M.
    Arance, A.
    Bondarenko, I.
    Haanen, J. B. A. G.
    Hansson, J.
    Utikal, J.
    Ferraresi, V.
    Mohr, P.
    Probachai, V.
    Schadendorf, D.
    Nathan, P.
    Robert, C.
    Ribas, A.
    Davies, M. A.
    Lane, S. R.
    Legos, J. J.
    Mookerjee, B.
    Grob, J. -J.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (07) : 1631 - 1639
12345